Tyrosine kinase inhibitors seem safe in CML with CKD

Tyrosine kinase inhibitors seem safe in CML with CKD
Tyrosine kinase inhibitors appear to be safe in patients with chronic-phase chronic myeloid leukemia and chronic kidney disease, according to a study published online July 28 in Cancer.

(HealthDay)—Tyrosine kinase inhibitors (TKIs) appear to be safe in patients with chronic-phase (CP) chronic myeloid leukemia (CML) and chronic kidney disease (CKD), according to a study published online July 28 in Cancer.

Musa Yilmaz, M.D., from the Baylor College of Medicine in Houston, and colleagues examined the incidence of (AKI) and CKD in 468 newly diagnosed -, dasatinib-, and nilotinib-treated CP CML patients. From the start of therapy to the last follow-up, the authors assessed molecular and cytogenetic response data, creatinine, and glomerular filtration rate (GFR).

The researchers found that 4 percent of patients had TKI-linked AKI. Compared with dasatinib and nilotinib, imatinib correlated with increased incidence of AKI (P = 0.014). Fourteen percent of patients developed CKD while receiving a TKI, of whom 84 percent were receiving imatinib (P < 0.001). The development of CKD correlated with imatinib, age, history of hypertension, and diabetes mellitus. Imatinib reduced GFR over time in patients with no CKD at baseline, while in patients with a history of CKD, imatinib did not cause a significant decline in GFR. After three months of treatment, imatinib, dasatinib, and nilotinib increased the mean GFR, with the most significant increase for nilotinib (P < 0.001).

"The administration of TKIs may be safe in the setting of CKD in CP CML patients, but close monitoring is still warranted," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.


Explore further

CKD, glomerulonephritis risk higher for those with psoriasis

More information: Abstract
Full Text (subscription or payment may be required)
Journal information: Cancer

Copyright © 2015 HealthDay. All rights reserved.

Citation: Tyrosine kinase inhibitors seem safe in CML with CKD (2015, August 1) retrieved 24 August 2019 from https://medicalxpress.com/news/2015-08-tyrosine-kinase-inhibitors-safe-cml.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
57 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more